What Xact Laboratories does

Xact Laboratories, LLC is a privately held, CLIA-certified pharmacogenomic (PGx) testing company founded in 2012 and headquartered in Twinsburg, Ohio. The company operates two core products: XactMed4U, a comprehensive genetic testing panel covering 200+ medications and 15+ gene variants across cardiovascular, psychiatric, pain management, and metabolic therapeutic areas using next-generation sequencing and real-time PCR; and XVIS (Xact Vertical Integration System), a patent-pending interoperability platform that delivers PGx insights natively into Epic, Cerner, HL7 FHIR-compliant systems, pharmacy benefit managers, retail pharmacy systems, and payer claims platforms via RESTful APIs and webhooks. The platform combines an automated prior authorization clearinghouse with rules-based prescription interception logic that flags genetically ineffective medications before they are dispensed, with company-disclosed outcomes of 95% accuracy in predicting drug response, 40-45% reduction in adverse drug reactions, and $2.3M average annual savings per health system.

The business model spans three revenue streams: per-test pharmacogenomic testing services (one-time license model on enterprise contracts), non-exclusive technology licensing of the patented integration and prior authorization IP to healthcare technology buyers, and recurring evidence-based prescribing services sold on multi-year contracts to payers, PBMs, and self-insured employers on a value/outcomes basis. The company sells primarily through an enterprise field sales motion targeting health insurance payers, PBMs, hospital systems, and self-insured employer groups, supplemented by industry-conference presence (NCPDP Annual Technology & Business Conference), PR Newswire distribution for patent and award announcements, and inbound enterprise demo requests through the website. Pricing is quote-based with no publicly disclosed price points, and no named enterprise customers, revenue figures, or institutional funding rounds appear in available data. The intellectual property position is unusually broad for an 11-50 employee company, with 8 issued US patents and 5 pending applications accumulated between 2022 and 2026 covering formulary overlays, automated prior authorization, real-time genetic data transmission, and pharmacy fill-blocking.

Name

Xact Laboratories

Legal name

Xact Laboratories, LLC

Website

https://xactlaboratories.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Xact Laboratories is a CLIA-certified pharmacogenomic testing company that combines the XactMed4U genetic test panel with the XVIS integration platform to deliver PGx insights, automated prior authorization, and prescription interception into EHR, PBM, payer, and pharmacy workflows for enterprise healthcare buyers.

Ownership category

akta.pro rank

Product category

Pharmacogenomic Testing and Precision Medicine Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Pharmacogenomics (PGx) Decision Support (HLAAANAB)

akta.pro secondary industries

Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), PBM Technology Platforms (ePA/eRx/Real-Time Benefit Tools) (HLAEAKAL)

Keywords

• Pharmacogenomic testing services
• Precision medicine diagnostics
• Automated prior authorization
• EHR clinical decision support
• Pharmacy benefit integration

Headquarters

HQ city

Twinsburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Pharmacogenomic Testing Services: Revenue generated from providing comprehensive pharmacogenomic testing panels (XactMed4U and XVIS products) to healthcare providers, payers, PBMs, and health systems. Testing covers 200+ medications and 15+ gene variants with real-time results delivered via EHR integration.
2. Technology Licensing: Non-exclusive licensing opportunities offered to organizations looking to integrate clinical PGx workflows. Patent-protected technology available for licensing to healthcare technology companies, payers, and pharmacy systems.
3. Evidence-Based Prescribing Services: Services targeted at payers, PBMs, health systems, and self-insured employer groups providing value-based outcomes including improved STAR and HEDIS ratings, reduced total medical spend, and improved medication adherence.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Xact Laboratories operates a CLIA-certified laboratory and software platform that delivers comprehensive pharmacogenomic (PGx) testing covering 200+ medications and 15+ gene variants. Its XactMed4U testing panel combines a patient-friendly cheek swab with AI-enhanced prescription decision support, while its patent-pending XVIS integration system pushes genetic insights in real time into Epic, Cerner, PBM, payer and health information exchange systems. The company's proprietary automated prior authorization clearinghouse intercepts potentially harmful or ineffective prescriptions before dispensing and suggests formulary-aligned alternatives.

Product overview

Xact Laboratories offers a unified pharmacogenomic testing platform comprising two core products: XactMed4U, a comprehensive genetic testing panel covering 200+ medications and 15+ gene variants using next-generation sequencing and real-time PCR analysis; and XVIS, a patent-protected vertical integration system that delivers clinically actionable PGx insights across all major healthcare platforms including Epic, Cerner, HL7 FHIR, pharmacy benefit managers, and payer systems. The platform combines automated prior authorization clearinghouse technology with AI-enhanced prescription decision support to intercept potentially harmful medications before dispensing, achieving 95% accuracy in predicting drug response and 40% reduction in adverse drug reactions. Services are delivered through seamless EHR integration with real-time clinical decision support within provider native workflows.

Differentiator

Problem solved

Functional benefit

Brands

• XactMed4U: Comprehensive pharmacogenomic testing platform covering multiple therapeutic areas for personalized medicine, featuring automated prior authorization and AI-enhanced prescription decision support.
• XVIS

Products and services

• XactMed4U Comprehensive pharmacogenomic testing panel covering 200+ medications and 15+ gene variants across cardiovascular, psychiatric, pain management and metabolic therapeutic areas. Combines a patient-friendly cheek swab with patented automated prior authorization technology and AI-enhanced prescription decision support to deliver precision medicine at the point of care. Targets healthcare providers, payers, PBMs and self-insured employer groups.
• XVIS (Xact Vertical Integration System) Patent-pending interoperability platform that delivers clinically actionable pharmacogenomic insights within provider's native and familiar workflow. Seamlessly integrates with every major healthcare platform—payers, PBMs, pharmacy systems, HIEs and EHR systems (Epic, Cerner)—through RESTful APIs, webhooks and HL7 FHIR-compliant data exchange. Provides contextual clinical decision support, automated prior authorization, claims processing integration and formulary optimization in real time.
• PGx Testing Services Evidence-based prescribing services delivered through the CLIA-certified Xact Laboratories laboratory, including pharmacogenomic testing with automated medication safety checks prior to pickup, outcomes optimization for payers/PBMs/health systems/self-insured employers, and convenient testing at the pharmacy counter. Targets enterprise healthcare buyers seeking improved STAR/HEDIS ratings, reduced total medical spend, and improved medication adherence.

Quantifiable outcome

• 95% accuracy rate in predicting drug response based on genetic markers
• +8 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability5 records

Feature4 records

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• OneOme: OneOme provides a RightMed PGx test and decision-support platform with EHR integration, directly competing with XactMed4U and XVIS for payer and health system contracts in personalized prescribing.
• Coriell Life Sciences: Coriell Life Sciences offers enterprise PGx services with pharmacogenomic interpretation and decision-support tools, serving payers, PBMs, and health systems in direct competition with Xact.
• Genomind: Genomind offers the GeneSight PGx test, the most established direct competitor in pharmacogenomic decision support, with similar focus on mental health medications and integration into prescriber workflows.
• Myriad Genetics: Myriad Genetics operates GeneSight (acquired via Myriad Neuroscience) and broader PGx offerings, making it a large, well-capitalized competitor with established payer contracts in the same therapy-selection niche.
• Genelex: Genelex provides YouScript, a PGx testing and clinical decision support platform for clinicians, with comparable focus on integrating genetic insights into prescribing workflows.

Emerging players

• Sema4: Sema4 (now part of GeneDx) offers genomic and pharmacogenomic testing with health system integration, competing with Xact in advanced clinical decision support for personalized prescribing.
• Color Health: Color Health provides population-scale genetic testing with employer and health system channels; while broader than pure PGx, it overlaps with Xact in employer-sponsored pharmacogenomic and preventive programs.

Broad incumbents

• Mayo Clinic Laboratories: Mayo Clinic Laboratories is a major reference laboratory offering PGx panels alongside broad diagnostic services, competing with Xact's CLIA-certified lab for hospital and health system volume.
• Invitae: Invitae is a large-scale clinical genetic testing company with broader hereditary disease focus but overlapping pharmacogenomic and therapy-selection capabilities aimed at health systems.
• Quest Diagnostics: Quest Diagnostics is a national reference lab offering pharmacogenomic and clinical decision support through its Cardio IQ and PGx panels, with substantially larger scale and payer reach than Xact.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xact Laboratories